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Abstract.  The conversion of latent transforming 
growth factor beta (LTGF-/~) to the active species, 
transforming growth factor beta (TGF-/5),  has been 
characterized in heterotypic cultures of bovine aortic 
endothelial  (BAE) cells and bovine smooth muscle 
cells (SMCs).  The formation of TGF-B in co-cultures 
of BAE cells and SMCs was documented by a  specific 
radioreceptor competition assay, while medium from 
homotypic cultures of BAE cells or SMCs contained 
no active TGF-~ as determined by this assay.  The con- 
centration of TGF-B in the conditioned medium of het- 
erotypic co-cultures was estimated to be 400-1,200 
pg/ml using the inhibition  of BAE cell migration  as an 
assay.  Northern blotting of poly A + RNA extracted 
from both homotypic and heterotypic cultures of BAE 
cells and SMCs revealed that BAE cells produced both 
TGF-/31 and TGF-B2, while SMCs produced primarily 
TGF-J51. No change in the expression of these two 
forms of TGF-/3 was apparent after 24 h in heterotypic 
cultures.  Time course studies on the appearance of 
TGF-/3 indicated that most of the active TGF-/5 was 
generated within the first 12 h after the establishment 
of co-cultures.  The generation of TGF-/3 in co-cultures 
stimulated the production of the protease inhibitor 
plasminogen activator inhibitor-1  (PAI-1). The inclu- 
sion of neutralizing  antibodies to TGF-/3 in the co- 
culture medium blocked the observed increase in PAI- 
l  levels.  The increased expression of PAI-1 subsequent 
to "I'GF-/5 formation blocked the activation of the pro- 
tease required for conversion of LTGF-~3 to TGF-/~ as 
the inclusion of neutralizing  antibodies to PAI-1 in the 
co-culture medium resulted in prolonged production of 
TGF-B.  This effect was lost upon removal of the PAId 
antibodies.  Thus,  the activation of LTGF-~ appears to 
be a  self-regulating  system. 
T 
RANSFORMING growth  factor B (TGF-/~)  ~ is a homo- 
dimeric protein with a  molecular weight  of 25,000. 
TGF-/~ is produced by a variety of cells in vitro (16, 
34) and has been isolated from a number of tissue sources 
(2, 8, 24). The purified protein displays a variety of activities 
in a cell specific manner.  These include the induction of ma- 
trix macromolecule synthesis (3, 6, 12), decreases in the syn- 
thesis of the proteases collagenase and plasminogen activator 
(PA) (5, 15, 27) and stimulation  of the synthesis of irthibitors 
of both collagenase and PA (5,  14, 30). TGF-B is a strong 
chemoattractant and mitogen for some cell types (3, 25, 36), 
although it blocks the migration and growth of other cells (7, 
10, 21,  26,  28,  35).  These activities suggest  that  a  major 
physiological  role of TGF-B may be in wound healing. 
Although TGF-/5 has a widespread distribution,  the mole- 
cule usually is isolated as an inactive  high molecular mass 
1. Abbreviations used in this paper: BAE, bovine aortic endothelial; PAI-I, 
plasminogen activator inhibitor 1; SMC, smooth muscle cell; TGF-B, trans- 
forming growth factor beta; LTGF-B, latent transforming growth  factor 
beta. 
complex (16, 37). This inactive complex has been shown to 
contain the 25,000-D TGF-/3 homodimer in noncovalent as- 
sociation  with  the  amino-terminal  region  of the  TGF-/~ 
precursor  (17a, 19,  38).  The  latent  TGF-B complex iso- 
lated from platelets  contains an additional,  unrelated  mole- 
cule that  is covalently  bound (19, 38).  The latent  form of 
TGF-/5 (LTGF-/~) does not bind to the TGF-B receptor (16, 
22). However, LTGF-B can be converted into the active form 
by strong acid (pH 2) treatment.  Although mildly acidic en- 
vironments  occur in vivo, activation  of LTGF-B by acid pH 
has not been demonstrated to occur in either in vivo or in 
vitro biological systems.  Purified LTGF-/~ can be activated 
by plasmin or cathepsin  D (17). Recent studies suggest that 
proteases,  specifically  plasmin,  act by cleaving  within  the 
amino-terminal  region of the TGF-B precursor, thereby de- 
stabilizing  the latent  complex and  releasing  active  TGF-B 
(17a). 
Recently, two reports described the conversion of LTGF-/~ 
to the active  species in co-cultures of endothelial  cells and 
pericytes or smooth muscle cells (SMCs) (1, 29). Antonelli- 
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mitosis by pericytes which they had described previously 
(20) resulted from the formation of TGF-/~ in heterotypic co- 
cultures. In a similar set of  experiments, Sato and Rifkin (29) 
found that pericytes or SMCs blocked endothelial cell move- 
ment and that this effect also depended upon the formation 
of TGF-/3 from its inactive precursor.  All three of the cell 
types examined appeared to secrete only LTGF-/5 in homo- 
typic cultures, while in heterotypic cultures activation oc- 
curred. Activation appeared to require cell-cell contact or 
the very close apposition of the two different cell types. The 
activation reaction also required plasmin as inclusion of in- 
hibitors  of  plasmin  in  the  heterotypic  culture  medium 
blocked  the  formation  of TGF-/3 (29).  This  observation 
agreed with the previous results of Lyons et al. (17) that plas- 
min will convert LTGF-B to TGF-~. 
Since most cultured cells appear to produce only LTGF-/3, 
the activation reaction may be a critical regulatory step. To 
better understand the mechanism of activation, we have ex- 
tended our analysis of the activation reaction. We have found 
that both the heterotypic and homotypic cultures produce 
both LTGF-~I and LTGF-/32 and that there is no significant 
increase in TGF-~ mRNA abundance in heterotypic cul- 
tures. Approximately 1-10% of the inactive species is con- 
verted to the active form in co-cultures. The activation reac- 
tion is dependent upon the length of time the two cell types 
are co-cultured and the activation product, TGF-~/, induces 
the synthesis of plasminogen activator inhibitor 1 (PAl-l). 
PAI-1 blocks subsequent conversion of plasminogen to plas- 
min,  thereby  suppressing  further  activation  of  LTGF-/~. 
Thus, the system appears to self-regulate. 
Materials and Methods 
Cell Culture 
Bovine aortic endothelial (BAE) cells and bovine pericytes were grown in 
alpha  minimal  essential  (aMEM)  and bovine  SMCs  were  isolated  and 
grown in DME as described previously (29). Cells were used between pas- 
sages 7 and 15. 
Preparation of Conditioned Medium 
BAE cells and SMCs were passaged using 0.25% trypsin 0.1 mM EDTA, 
and the trypsin neutralized with aMEM plus  10% calf serum.  Cells were 
centrifuged and resuspended in serum-free aMEM containing 0.1% BSA. 
BAE cells  and  SMCs  were  seeded  separately  at 5  x  los cells/era  2 in 
aMEM  plus 0.1% BSA. For co-culture experiments, 4  x  l0  s BAE cells 
plus 1 ×  los SMCs/cm  2 were seeded in the same dish in aMEM plus 0.1% 
BSA. Cells were incubated at 37°C for 2 h to allow them to attach to the 
surface, and then changed to fresh aMEM plus 0,1% BSA (0.1 mi/cm2). 
After the appropriate incubation, the medium was collected and centrifuged 
to remove debris. For time course experiments, the medium was collected 
at the indicated times and replaced with the same volume of fresh medium. 
Concentration of Conditioned Medium 
Conditioned medium from homo- or heterotypic cultures was collected af- 
ter 24 h of incubation and 20 #g/ml of aprotinin (Sigma Chemical Co., St. 
Louis, MO) was added. The conditioned medium was concentrated 50-fold 
by ultra filtration (molecular weight cut off  at 10,000). All procedures were 
carded nut at 4°C, and the concentrated medium was stored at 4"C before 
assay. 
Wound Assays and Ceil Migration in the Presence 
of  a Second Cell ~ype 
Each of these techniques was performed exactly as described (29). 
TGF-[3 Radioreceptor  Assay 
This assay was performed as described by Lyons et al. (17) except that the 
AKR-2B (clone 84A) cells were preincubated for 1 h at room temperature 
in binding buffer. The binding buffer consisted of 128.0 mM NaCI, 5.0 mM 
KC1, 5.0 mM MgSO4, 1.2 mM CaC12, 50,0 mM Hepes pH 7.5, and 2.0 
mg/rni BSA. The buffer was stored at 4°C and filtered through a 0.5-/~m 
filter before use. The solubilization buffer was 1.0% Triton X-100, 0.1% 
BSA, 0.02% sodium azide in PBS. Nonspecific binding was determined in 
the presence of a 400-fold excess of unlabeled TGF-fll and was <25 %. 
Northern Blots 
RNA was extracted by the method of Schwab et al. (31). Oligo (dT) select- 
ed RNA was separated by electrophoresis in a 1.2 % agarose-formaldehyde 
gel. Transfer and hybridization of RNA was performed as previously de- 
scribed (33). Northern blots were probed with eDNA inserts isolated from 
plasmids containing the following genes: TGF-/$1 (4), TGF-B2 (18). cDNAs 
were labeled using a random primer extension method (32). All Northern 
blots were hybridized with a control mouse GAP probe (5) and signals nor- 
malized by laser densitometry.  All hybridizations and washes were per- 
formed at 42°C. 
Antisera 
Rabbit anti-porcine  TGF-~ IgG was purchased from R & D Systems (Min- 
neapolis, MN). The antibody neutralizes both porcine and human TGF-~ 
(13). The antibody does not cross-react with either acidic or basic FGF, 
PDGF, or EGF, and neutralizes the TGF-B stimulation of anchorage inde- 
pendent growth of  rabbit kidney ceils. Neutralizing rabbit anti-bovine PAI-I 
serum was a generous gift from D. Loskutoff (Scripps Clinic and Research 
Foundation, La Jolla, CA). IgG fractions from anti-PAid sera were pre- 
pared by chromatography on protein A-Sepharose (Pharmacia Fine Chemi- 
cals, Piscataway, NJ). 
Immunoprecipitations 
Quantitative immunoprecipitations of PAI-I were carded out in the follow- 
ing manner. Conditioned medium containing [35S]methionine  (40 ttCi/ml, 
100 mCi/mMol,  New England Nuclear, Boston, MA) was collected from 
60-mm dishes of either homo- or heterotypic cultures of BAE cells and 
SMCs after  16 h of incubation. The conditioned medium was centrifuged 
in an Eppendorf tube (made by Brinkmann Instruments,  Inc.,  Westbury, 
NY) at 10,000 rpm for 10 min. 500 #l of  the supernatant was then incubated 
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Figure 1. Radioreceptor inhibition assay for TGF-/L Medium from 
cultures of  BAE cells or BAE ceils and SMCs was concentrated 50- 
fold and assayed for its ability to compete with mI-TGF-/~  binding 
to AKR-2B (clone 84A) cells. The conditioned medium was col- 
lected after a 24-h incubation with the cells. Results are presented 
as  percent inhibition of binding after correction for nonspecific 
binding. (A) TGF-~ standard; (~7) medium conditioned by co-cul- 
tures of  BAE ceils and SMCs; (o) medium conditioned by cultures 
of BAE cells. The dashed lines represent lines used for the calcula- 
tion of the amount of TGF-/~ present by extrapolating from the ac- 
tivity of the co-culture medium to the standard curve. 
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Heterotypic Cultures 
Sample  Treatment  TGF-/$ 
(ng/ml) 
BAE  None  ND 
BAE  +  SMCs  None  0.02 
BAE  pH  1.5  8 
Pericytes  pH  1.5  4 
BAE  +  Pericytes  pH  1.5  12.5 
BAE  pH  1.5  5 
BAE  +  SMC  pH  1.5  11 
Conditioned medium from homotypic or heterotypic cultures of BAE cells and 
pericytes  was  prepared  and  concentrated  as  described  in  Materials  and 
Methods. The medium was divided in half; one part was treated with acid (pH 
1.5, 1 h), while the other was held as a control. The amount of TGF-B in each 
sample was then computed by using the receptor inhibition assay. The values 
for TGF-B represent the concentrations in the original medium. ND, not de- 
tectable. 
with 20 #1 of either immune or nonimmune serum for I h at room tempera- 
ture. At this time 40 #1 of protein A-Sepharose beads were added and a fur- 
ther l-h incubation at room temperature carried out. The solution was cen- 
trifuged at 10,000 rpm for 10 rain. The beads were washed three times with 
a 1:1 solution of PBS:RIPA buffer (10 #M Tris hydrochloride Loll 7.4]; 0.15 M 
NaCI;  1%  sodium deoxycholate;  1%  NP-40;  0.1%  SDS;  1 mM EDTA; 
10 mM KCI; 20 gg aprotinin/ml) and centrifuged at 10,000 rpm for 10 min 
after each wash. The beads were then washed once with distilled water and 
centrifuged at 10,000 rpm for 10 rain. 40 #1 of 4x sample buffer was added 
to the beads and the sample boiled for 10 min. The contents of the tube were 
then subjected to SDS-PAGE. The gel was then analyzed by autoradiogra- 
phy followed by densitometry scanning (23). Different exposure times were 
used to insure that the density of the spot on the autoradiography film was 
in the linear range of the densitometer used to quantitate the PAId bands. 
Subsequent incubation of the initial supernatant with additional antiserum 
or protein A-Sepharose beads failed to reveal additional radioactivity which 
could be immunoprecipitated. Control experiments with nonimmune rabbit 
serum also failed to demonstrate any immunoprecipitation of PAl-1. 
Results 
Our previous identification of the migration inhibiting mole- 
cule formed upon co-cultivation of ECs with SMCs or peri- 
cytes as TGF-/3 relied primarily upon the specificity of neu- 
tralizing TGF/~-I IgG (29). Since the antibodies used in these 
studies were polyclonal and might have had secondary reac- 
tivities, we attempted to demonstrate the presence of TGF-/~ 
by a specific radio-receptor competition assay. In this assay 
J2SI-TGF-/~I binding to its receptor is measured in the pres- 
ence of the test solution and the concentration of TGF-/~ pres- 
ent  computed  by  the  degree  of inhibition  of  ~25I-TGF-/3 
binding to AKR-2B cells.  Pure porcine TGF-ffl is used in 
this assay to generate a standard curve for comparison and 
concentration  estimates.  LTGF-~I  does  not  compete  for 
binding to the TGF-/~ receptor and, therefore, does not inter- 
fere with the assay. Our initial attempts to measure TGF-/3 
in  the  medium  from co-cultures  of ECs  and  SMCs  were 
negative indicating that the TGF-/~ concentration was below 
the detection limit of the assay (500 pg/ml). However, if the 
conditioned medium was concentrated 50-fold before being 
assayed, competing material was detected in the co-culture 
conditioned medium (Fig.  1). 
The degree of inhibition corresponded to a TGF-/~ concen- 
tration of 20 pg/ml in the original co-culture medium. No 
competing activity was observed in the conditioned medium 
from the homotypic cultures of BAE cells (Fig. 1). If  the con- 
ditioned medium from either homo- or heterotypic cultures 
was treated with acid followed by reneutralization to convert 
the LTGF-B to the active form (16, 17), ,o4-12 ng/rnl of TGF-/~ 
was found in medium conditioned either by BAE cells, SMCs, 
pericytes, or co-cultures. Therefore, active TGF-B accounted 
for ,01% of the total LTGF-B. This value may well be an un- 
derestimate since measurements of TGF-/3 generated in cell 
culture systems of this type may be low because active TGF-/3 
will be removed from the medium by high affinity receptors, 
while LTGF-/5 will not. While both ECs and SMCs appeared 
to produce LTGF-3, active TGF-/3 was found only in condi- 
tioned medium of heterotypic cultures. Although a somewhat 
greater total amount of TGF-~ was found in heterotypic cul- 
ture medium than in homotypic culture medium (Table I), 
it is unlikely that this difference accounted for the active TGF-B 
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Figure 2. Inhibition of BAE cells migration by increasing I"GF-~I 
concentrations.  Confluent monolayers of BAE cells were wounded 
as described in Materials and Methods. The cells were allowed to 
migrate overnight, and the monolayers were fixed, stained, and the 
number of cells that had crossed the original wound margin counted. 
Data are expressed as a percent of migration observed in a control 
untreated wound.  (*) TGF-/~I added postwounding;  (A) "rGF-/~I 
added 3 h prewounding and removed postwounding;  (o) TGF-/$1 
present  3 h prewounding and throughout postwounding. 
~lO0 
§ 8o 
'*6 
~_.  6O 
8 
"=  40 
"E 20 
0 
L.  I  I  l  llllll  I  I  I  IIIIII  I  I  l  l  lllll 
o  I  IO  IOO 
% of coculture conditioned medium 
Figure 3.  Effect of acid treatment  on co-culture  conditioned  me- 
dium.  Confluent monolayers of BAE cells were wounded as de- 
scribed in Materials and Methods. The medium was replaced with 
varying concentrations of conditioned medium from co-cultures of 
BAE ceils and SMCs or the same medium that had been treated at 
pH 2 for 1 h at 4°C. The co-culture conditioned medium was col- 
lected after a 24-h incubation with the cells. The cultures were in- 
cubated overnight, and the cells fixed, stained,  and counted.  The 
wounded BAE cell number of cells that had migrated  across the 
original wound margin is expressed as a percentage of the number 
of cells that had migrated in a control culture which received nor- 
mal medium. (e) Co-culture conditioned medium; (o) acid-treated 
conditioned medium. 
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Figure 5.  Time course of inhibition of BAE cell movement. Con- 
fluent monolayers of BAE cells were wounded as described in Ma- 
terials and Methods. After wounding, the medium was replaced ei- 
ther with control medium, medium containing TGF-B1 (300 pg/ml), 
or medium from co-cultures of BAE cells and SMCs. This latter 
medium was collected after a 24-h incubation.  The cultures were 
incubated for the times indicated. The cultures were then fixed and 
stained and the number of cells that had migrated across the initial 
wound boundary  counted.  The results are expressed as a percent 
of the total number of cells that migrated in control, basal medium 
after 20-h incubation. (e) Migration in basal medium; (o) migra- 
tion io the presence of "I'GF-#I (300 pg/ml);  (A) migration in the 
presence of SMCs. 
Figure 4. Expression of  TGF-/31 and TGF-/~2  by homotypic and het- 
erotypic cell cultures. Poly (A  ÷) RNA was isolated from cell mono- 
layers after 24 h in culture.  The mRNA was then separated  and 
transferred as described in Materials and Methods. The transferred 
mRNA was probed with the indicated 3zP-labeled cDNAs and cor- 
responding transcripts  were identified by autoradiography.  Tran- 
script sizes were TGF-/31 (2.4 kb); TGF-/~2  (5.1 and 4.1 kb); mGAP 
(1.5 kb).  Homotypic cultures of BAE cells and SMCs, as well as 
heterotypic cultures consisting of ratios ofBAE: SMC (9:1, 4:1, hi) 
are as indicated. 
seen in heterotypic cultures. This requirement for heterotypic 
co-culture for activation of LTGF-/5'I as established by the 
radioreceptor inhibition assay confirms the previous results 
employing either cell migration (29) or cell division (1) to 
detect LTGF-/~ activation. 
When the concentration of exogenous TGF-/~I required to 
block cell migration was measured, concentrations as low as 
30 pg/ml were found to be effective (Fig. 2). The inhibitory 
response was independent of whether the exogenous, pure 
TGF-~ was added 3 h prewounding or was added immedi- 
ately postwounding. If the TGF-/31 was added 3-h prewound- 
ing and kept in the cultures throughout the experiment, inhi- 
bition was observed between 3  and  10 pg/ml (Fig.  2). 
If different dilutions of medium from heterotypic cultures 
were tested (Fig. 3), strong inhibitory activity was apparent 
at a 1:10 dilution. If the co-culture medium was acid-treated 
and assayed for its migration inhibitory activity (Fig.  3), it 
was apparent that acid treatment resulted in an approximate 
10-fold increase in inhibitory activity. If the total concentra- 
tion of LTGF-/3 was 4-12 ng/ml (Table I), the 10-fold increase 
indicates that the active TGF-/~ concentration in heterotypic 
co-cultures was 400-1,200  pg/mi rather than the 20 pg/ml 
calculated from the receptor competition assay. The simplest 
explanation for these apparently contradictory results is that 
the actual concentration of TGF-/3 in the co-culture medium 
may be higher than that revealed by the receptor competition 
assay and that some TGF-/~ was lost during the preparation 
of the co-culture medium for the receptor competition assay. 
A control experiment in which ~25I-TGF-B  was added to the 
conditioned  medium  before  concentration  indicated  that 
only 20%  of the added  radioactivity was recovered in the 
retentate (data not shown). 
Since several forms of TGF-/3 exist, we attempted to iden- 
tify by Northern blotting the species of TGF-/~ produced in 
both homo- and heterotypic cultures.  Northern blotting of 
poly A ÷ RNA  extracted  from BAE cells,  SMCs  and  co- 
cultures of BAE cells and SMCs revealed that both cell types 
produced TGF-/31 mRNA (Fig. 4). The BAE cells also con- 
tained TGF-fl2 mRNA while the SMCs expressed little if any 
TGF-fi2.  The expression of TGF-fi3 mRNA was not mea- 
sured.  Laser densitometric analysis of Northern blots fol- 
lowed by normalization to the MGAP constitutive transcript 
for each lane  independently  indicated  that  message levels 
were equivalent for all conditions examined at 24 h.  These 
results  agree with  the  measurements of TGF-fl protein in 
homo- and heterotypic cultures (Table I) in that there is no 
significant increase in the level of TGF-fl expression observed 
after co-culture. 
We next measured the time course of inhibition of migra- 
tion after addition of TGF-/31 or SMCs to wounded BAE cell 
monolayers (Fig.  5).  For the first 4-h after initiation of the 
experiment,  BAE cells in control cultures migrated at the 
same rate as  cells  in  cultures  to  which  either  TGF-~I or 
SMCs had been added after wounding. After 4 h, cell migra- 
tion in the co-cultures or TGF-/~l-treated cultures decreased. 
Between 4  and 8 h after initiation of the experiment, a sig- 
nificant difference between the rates of migration of treated 
and untreated cells was observed. By 20-h after wounding, 
there was a 40-50% difference between treated and untreated 
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Figure 6. Time of appearance of 
TGF-/~ in co-culture.  BAE ceils 
and  SMCs  were plated  together 
under  the  conditions  indicated. 
After 12 h, the medium was re- 
moved, placed on ice, and fresh 
medium containing additions add- 
ed.  This was repeated  at 24 and 
36 h.  The media from the three 
times (12, 24, and 36 h) were then 
assayed for the ability  to  affect 
BAE cell migration by addition to 
confluent monolayers of  BAE cells 
that  had  been  wounded  as  de- 
scribed  in  Materials  and  Meth- 
ods.  After an overnight incuba- 
tion, the cells were fixed, stained, 
and the number of cells that had migrated across the wound edge were counted.  (A; e) Conditioned medium from BAE cells; (&) condi- 
tioned medium from SMCs;  (o) conditioned medium from co-cultures of BAE cells and SMCs; (v) conditioned medium from cultures 
of BAE cells and SMCs plus nonimmune IgG (400 t~g/ml). (B; e) Conditioned medium from BAE cells; (n) conditioned medium from 
cultures of BAE cells and SMCs plus anti-PAI-I  IgG (400/~g/ml);  (e) conditioned medium from cultures of BAE cells and SMCs plus 
anti-PAI-1 IgG (400 #g/ml) that was removed and replaced at 24 h with medium containing nonimmune IgG (400 t~g/ml); 0arge *) control, 
BAE cell migration in the presence of anti-PAI-1 IgG; (*) control BAE cell migration  in the presence of nonimmune IgG. The results 
are expressed as a percentage  of cell movement in control wounded monolayers incubated overnight. 
cultures. These results implied that active TGF-/3 is formed 
rapidly in co-cultures since the time course of inhibition was 
similar  in  wounded  co-cultures  or  TGF-B1  supplemented 
cultures. 
Therefore, we next characterized the appearance of TGF-~ 
in co-cultures of BAE cells and SMCs as a function of time 
after mixing of the two cell types. In this experiment, co- 
cultures of BAE cells and SMCs  were established and in- 
cubated for 36 h. The medium was replaced every 12 h and 
at the end of the experiment the presence of TGF-/~ in the 
samples was assessed by the  wound  migration assay.  The 
results (Fig. 6) indicated that the production of TGF-~ was 
transient.  Thus, there was significant inhibitory activity in 
the medium collected 12 h after the initiation of co-culture, 
but a  rapid loss of inhibitory activity occurred during the 
subsequent 12-h period. By 24-36 h, no active "I'GF-/~ was 
detectable in the medium. This result was predicted by Lyons 
et al. (1), who hypothesized that if LTGF-~ was activated in 
a  plasmin-mediated  reaction,  the  product,  TGF-/3,  would 
block further activation via the increase in the production of 
the plasminogen activator inhibitor of PAI-1. TGF-/~ is a po- 
tent stimulator of the synthesis of PAI-1. Since plasminogen 
activator converts the  zymogen plasminogen to the active 
protease plasmin, the production of PAI-1 will decrease plas- 
rain formation. Lyons et al. (17) proposed that TGF-~ would 
regulate its own activation if plasmin is responsible for the 
conversion of LTGF-/3 to TGF-~.  2 
The following experiments were performed to verify this 
hypothesis. First, we measured the ability of anti-PAI-1 anti- 
bodies to prolong the  period of TGF-/3  generation.  When 
2. It should be noted that although our experiments were carried out in the 
absence of serum, which is the source of the plasminogen, the cells were 
exposed to serum to inhibit the trypsinization reaction. This step presum- 
ably provides the necessary plasminogen. Furthermore, the activation of 
LTGF-B can be blocked by the inclusion of antibodies to plasminogen and 
by inhibiting the trypsinization with serum depleted of plasminogen (our 
unpublished  observations). All of  these procedures would be expected to in- 
hibit a  plasmin-dependent reaction. 
neutralizing antibodies to PAI-1 were added to heterotypic 
co-cultures, TGF-/~ continued to be formed for 36 h (Fig. 6), 
while in control heterotypic cultures, the formation of TGF-/3 
effectively ceased after 12 h (Fig. 6). If  the antibody to PAI-1 
was removed after 24 h,  a  rapid loss of inhibitory activity 
in the cultures was observed, presumably because of the in- 
crease in PAI-I in the medium. These results indicate that 
even though much of the PAI-1 normally found in the culture 
medium is inactive (11) sufficient active inhibitor must exist, 
perhaps transiently, to block the activation reaction. 
Second, we measured the levels of PAI-1 in co-cultures of 
BAE cells and SMCs as a function of time after plating. PAI-1 
synthesis was low in both BAE cells and SMCs but increased 
appreciably during the 16 h after co-culture (Table II). If the 
observed induction of PAI-1 resulted from the formation of 
TGF-/~, inclusion of neutralizing antibodies to TGF-B in the 
co-culture medium should block PAI-1 induction. When this 
was tested, the increase of PAI-1 synthesis was almost com- 
pletely blocked (Table II). The small increase in the PAI-1 
levels observed in the presence of antibodies to TGF-/~ may 
indicate that the antibodies were not totally effective in neu- 
tralizing all of the TGF-t~ formed. 
Discussion 
The experiments presented in this paper characterize the in 
vitro activation of LTGF-~8 by plasmin in co-cultures of ECs 
and SMCs. The radio-receptor inhibition assay and North- 
ern blots indicated that both TGF-B  1 and 2 are transcribed 
and that a small percentage of the LTGF-/~ produced is acti- 
vated.  Purified  TGF-BI  is  extremely active in  this  system 
with inhibitory effects on cell motility observed at concentra- 
tions as low as  10-20 pg/ml. Activation of LTGF-~ occurs 
rapidly after co-culture and reaches a maximum by 12 h. Af- 
ter that point, decreasing amounts of TGF-~ are formed. The 
decrease in TGF-/3 formation results from the stimulation of 
PAI-1  synthesis by TGF-~/.  The secreted PAI-1 inhibits the 
Sato et al.  TGF-~ Activation in Co-culture  761 Table II. Induction of  PAI-1 Synthesis in Co-cultures 
Cells  Additions  PAI-I level 
BAE  -  20 
SMC  -  22 
BAE  +  SMC  -  473 
BAE  +  SMC  +  anti-TGF-fl IgG  126 
BAE  +  SMC  +  nonimmune IgG  404 
Culture of BAE cells, SMCs, or co-cultures of BAE cells and SMCs were in- 
cubated for  16 h.  The medium was coUeeted  and immunoprecipitated with 
anti-PAl-1 IgGs. The immunoprecipitates were then analyzed by SDS-PAGE 
followed by autoradiography. The autoradiographs were quantitated by den- 
sitometry and the results integrated and presented as relative units. 
plasminogen activator catalyzed generation of plasmin that 
activates LTGF-fl. Neutralizing antibodies to TGF-fl block 
PAI-1 induction in heterotypic co-cultures, while neutraliz- 
ing antibodies to PAI-1 extend the period of LTGF-fl acti- 
vation. 
These experiments verify the hypothesis that TGF-fl for- 
mation may be a self-regulating system. At low concentra- 
tions of TGF-fl, the level of PA synthesis and activity will be 
sufficient to convert plasminogen to plasmin. This will result 
in the enhanced conversion of LTGF-fl to TGF-fl. As the level 
of TGF-fl increases,  PAI-1 synthesis will rise and plasmin 
formation decrease resulting in a decrease in the conversion 
of LTGF-fl to TGF-fl. During extended periods, it is possible 
that this reaction will oscillate between activation and inhibi- 
tion. The description by Antonelli-Olridge et al. (1) of long- 
term (14 d) generation of TGF-fl in co-cultures of endothelial 
cells may represent such a phenomenon. 
Several important questions remain unanswered with re- 
spect to TGF-fl formation in heterotypic co-cultures. First, 
our co-culture experiments indicate that only a fraction of 
the LTGF-fl is activated. This may in part reflect the rapid 
inhibition of the activation system combined with the con- 
tinued production of LTGF-fl. However, Antonelli-Orlidge et 
al. (1) have reported that in their co-culture system 100% of 
the LTGF-fl is activated. The reasons for this difference are 
not clear  but may reflect differences in the experimental 
methodology since Antonelli-Olridge et al. (1) used serum 
containing medium in some of their experiments. This may 
result in higher plasmin levels.  It is also possible that addi- 
tional mechanisms or requirements for activation exist. It 
should be noted, however, that in many proteolytic reactions, 
an excess of the substrate is present. 
Second, why does activation occur only with heterotypic 
co-cultures rather than homotypic cultures? Heterotypic cul- 
tures produce similar amounts of LTGF-fl as do homotypic 
cultures. One possibility is that changes in the plasminogen 
activator (PA) plasmin system occur upon heterotypic co- 
culture. An obvious change would be the induction of PA. 
However,  assays of PA levels in homotypic and heterotypic 
cultures have not revealed a stimulation of PA production or 
activity upon co-culture (unpublished observations). It ap- 
pears more likely that any changes in the PA-plasmin system 
that may occur involve modifications  of the level of periceUu- 
lar proteolysis and not total proteolysis. We are currently ex- 
ploring this possibility. A recent paper by Glick et al. (9) de- 
scribed the production of active TGF-fl2 by keratinocytes 
treated with retinoic acid. It is possible that retinoic acid in- 
duces the synthesis of all of the cellular components required 
for the activation of LTGF-fl. We are currently exploring this 
possibility. 
Finally,  the  in  vivo  significance of these  observations 
should be considered. Thus far, there are no data available 
on the in vivo activation of LTGF-fl or even on the in vivo 
role(s) of  endogenous TGF-fl. It is appealing to speculate that 
the in vivo regulation of LTGF-fl activation is mediated via 
cell-cell contact and the PA-plasmin  system in a  manner 
similar to the in vitro activation. Since TGF-fl acts as a nega- 
tive regulator, the contact of two different cell types would 
generate a molecule that blocks further cell movement and 
division. In the normal case, this might maintain tissue cyto- 
architecture. The sustained pathological interaction of cell 
types might lead to continued production of low levels  of 
TGF-fl. This may in turn result in the abnormal production 
of matrix. 
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